Advertisement

BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 600x60px
Document › Details

Expression Pathology Inc.. (2/1/12). "Press Release: Expression Pathology Appoints New President and CEO". Rockville, MD.

Organisation Organisation Expression Pathology Inc. (EPI)
  Today OncoPlex Diagnostics (OncoPlexDx)
  Group OncoPlex Diagnostics (OncoPlexDx)
Products Product Liquid Tissue® technology (Expression Pathology)
  Product 2 companion diagnostic test
Person Person Burrows, Jon (Expression Pathology 201202– CEO before Head R&D since 2009 before Ventana + Novartis + Chiron)
     


Expression Pathology Inc. announced today that Dr. Jon Burrows has been appointed President and Chief Executive Officer. Dr. Burrows has served as Expression Pathology's Head of R&D and Executive Vice President since 2009. He has been instrumental in the development of the company's technology platform and strategic direction. He replaces Mr. Casey Eitner, who will remain on the board of directors.

Dr. Burrows brings extensive experience in development of clinical tissue assays and a deep understanding of cancer pathways and drug development. Prior to joining Expression Pathology he held management roles at Ventana Medical Systems (a member of the Roche group) in business development and R&D with responsibilities for managing companion diagnostic development collaborations with major biopharmaceutical companies. Previous roles included research and management positions with Novartis, Chiron, Rigel and Sugen/Pharmacia.


About Expression Pathology

Expression Pathology is advancing personalized medicine assays that measure tumor signaling networks-at the functional protein level-in routine formalin-fixed paraffin-embedded (FFPE) patient tissue to individualize and improve cancer treatment decisions. The company is developing proprietary Liquid Tissue®-SRM companion diagnostic tests to support the development of drugs in clinical trials and to improve patient selection for targeted therapies already on the market. The company's rapidly expanding menu of assays includes many of the key protein pathways for which targeted therapies are being developed, including EGFR, IGF-1R, SPARC, SRC, HER2, HER3, and cMET.

For more information, please contact
Peter Tunon
Vice President, Sales and Marketing
Expression Pathology Inc.
9620 Medical Center Drive
Rockville, MD 20850
Phone: 301.977.3654
Email: p.tunon@expressionpathology.com


   
Record changed: 2016-03-19

Advertisement

Picture AB Sciex Berliner LCMSMS Symposium 2017 Middle 600x60px

More documents for OncoPlex Diagnostics (OncoPlexDx)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture AB Sciex Berliner LCMSMS Symposium 2017 Middle 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 120x180px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px